SELLAS Life Sciences (SLS) Assets (2010 - 2026)
SELLAS Life Sciences (SLS) reported Assets of $114.2 million for Q1 2026, up 226.63% year-over-year from $35.0 million in Q1 2025, and up 45.74% on a QoQ basis from $78.3 million in Q4 2025.
SELLAS Life Sciences (SLS) has 17 years of Assets data on file, last reported at $114.2 million in Q1 2026.
- Quarterly Assets rose 226.63% year-over-year to $114.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $114.2 million (up 226.63% YoY) and the FY2025 annual result came in at $78.3 million, up 303.18% from the prior year.
- Assets advanced to $114.2 million in Q1 2026 per SLS's latest filing, from $78.3 million in the prior quarter.
- Across five years, Assets topped out at $114.2 million in Q1 2026 and bottomed at $6.2 million in Q4 2023.
- The 5-year median for Assets is $26.0 million (2022), against an average of $32.9 million.
- The widest annual swing landed in 2023, when Assets slumped 70.31%; it then soared 303.18% in 2025.
- Tracing SLS's Assets over 5 years: stood at $20.9 million in 2022, then tumbled by 70.31% to $6.2 million in 2023, then soared by 212.46% to $19.4 million in 2024, then soared by 303.18% to $78.3 million in 2025, then jumped by 45.74% to $114.2 million in 2026.
- Per Business Quant, the three latest SLS Assets figures stand at $114.2 million (Q1 2026), $78.3 million (Q4 2025), and $51.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.13 Bn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | 114.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 114.18 Mn |
| Dec 31, 2025 | 78.35 Mn |
| Sep 30, 2025 | 51.56 Mn |
| Jun 30, 2025 | 32.31 Mn |
| Mar 31, 2025 | 34.96 Mn |
| Dec 31, 2024 | 19.43 Mn |
| Sep 30, 2024 | 26.51 Mn |
| Jun 30, 2024 | 15.12 Mn |
| Mar 31, 2024 | 24.43 Mn |
| Dec 31, 2023 | 6.22 Mn |
| Sep 30, 2023 | 8.09 Mn |
| Jun 30, 2023 | 18.57 Mn |
| Mar 31, 2023 | 29.10 Mn |
| Dec 31, 2022 | 20.94 Mn |
| Sep 30, 2022 | 26.00 Mn |
| Jun 30, 2022 | 32.21 Mn |
| Mar 31, 2022 | 21.43 Mn |
| Dec 31, 2021 | 26.28 Mn |
| Sep 30, 2021 | 37.95 Mn |
| Jun 30, 2021 | 43.62 Mn |
| Mar 31, 2021 | 40.58 Mn |
| Dec 31, 2020 | 46.05 Mn |
| Sep 30, 2020 | 18.51 Mn |
| Jun 30, 2020 | 14.51 Mn |
| Mar 31, 2020 | 17.03 Mn |
| Dec 31, 2019 | 16.61 Mn |
| Sep 30, 2019 | 21.48 Mn |
| Jun 30, 2019 | 25.03 Mn |
| Mar 31, 2019 | 14.93 Mn |
| Dec 31, 2018 | 16.92 Mn |
| Sep 30, 2018 | 38.47 Mn |
| Jun 30, 2018 | 31.97 Mn |
| Mar 31, 2018 | 33.49 Mn |
| Dec 31, 2017 | 33.53 Mn |
| Sep 30, 2017 | 49.60 Mn |
| Jun 30, 2017 | 60.55 Mn |
| Mar 31, 2017 | 70.33 Mn |
| Dec 31, 2016 | 6.42 Mn |
| Sep 30, 2016 | 72.85 Mn |
| Jun 30, 2016 | 73.78 Mn |
| Mar 31, 2016 | 66.37 Mn |
| Dec 31, 2015 | 82.14 Mn |
| Sep 30, 2015 | 82.67 Mn |
| Jun 30, 2015 | 101.97 Mn |
| Mar 31, 2015 | 108.61 Mn |
| Dec 31, 2014 | 80.49 Mn |
| Sep 30, 2014 | 79.49 Mn |
| Jun 30, 2014 | 80.28 Mn |
| Mar 31, 2014 | 92.29 Mn |
| Dec 31, 2013 | 87.98 Mn |
| Sep 30, 2013 | 91.25 Mn |
| Jun 30, 2013 | 62.00 Mn |
| Mar 31, 2013 | 61.45 Mn |
| Dec 31, 2012 | 54.99 Mn |
| Sep 30, 2012 | 35.19 Mn |
| Mar 31, 2012 | 28.21 Mn |
| Dec 31, 2011 | 30.97 Mn |
| Sep 30, 2011 | 30.33 Mn |
| Jun 30, 2011 | 32.35 Mn |
| Dec 31, 2010 | 7.48 Mn |